Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Clinical trial NCT05457010 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05457010
- Sponsor
- Arcellx, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-28
- Primary completion
- 2026-10-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.